PineBridge Investments’s Neurocrine Biosciences NBIX Stock Holding History

PineBridge Investments’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$437K	Buy	+3,315	New	+$440K	﹤0.01%	455
2025 Q2	–	Sell	-9,056	Closed	-$1M	–	683
2025 Q1	$1M	Sell	9,056 -21,059	-70%	-$2.67M	0.01%	500
2024 Q4	$4.11M	Sell	30,115 -227	-0.7%	-$28.1K	0.03%	348
2024 Q3	$3.5M	Buy	+30,342	New	+$4.16M	0.03%	363
2023 Q4	–	Sell	-12,399	Closed	-$1.39M	–	629
2023 Q3	$1.39M	Sell	12,399 -13,674	-52%	-$1.44M	0.02%	406
2023 Q2	$2.46M	Buy	26,073 +18,288	+235%	+$1.79M	0.03%	344
2023 Q1	$788K	Buy	+7,785	New	+$810K	0.01%	419

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PineBridge Investments's NBIX Position: Q1 2026 in Review

PineBridge Investments opened a new position in Neurocrine Biosciences (NBIX) in Q1 2026: 3,315 shares worth $437K. The stake represents ﹤0.01% of the portfolio and ranks #455 among its holdings. This is a return to the name: PineBridge Investments previously reported a position in NBIX as recently as Q1 2025.

PineBridge Investments first reported a position in NBIX in Q1 2023 and has held it in 7 quarters since. The position peaked at $4.11M in Q4 2024. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

PineBridge Investments held 3,315 shares of Neurocrine Biosciences worth $437K as of Q1 2026.
Neurocrine Biosciences was a new PineBridge Investments position in Q1 2026.
Neurocrine Biosciences made up ﹤0.01% of PineBridge Investments's portfolio in Q1 2026, its #455 holding.
PineBridge Investments first reported a position in Neurocrine Biosciences in Q1 2023 and has held it in 7 quarters since.
PineBridge Investments's Neurocrine Biosciences position peaked at $4.11M in Q4 2024.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on PineBridge Investments's 13F filing for Q1 2026, filed 14 May 2026.